Novacyt's unaudited revenue for 6 months of 2020 was €72.4 million, up 10 times from €7.2 million last year. This growth was driven by the sale of one of the world's first COVID-19 tests. Some supply contracts have been extended for the second half of 2020 and some for the entire year 2021. Novacyt expects a significant steady demand for their tests as the daily incidence of coronavirus continues to rise.